See the DrugPatentWatch profile for ruxolitinib
What patents cover ruxolitinib (Jakafi/Inrebic)?
Ruxolitinib’s patent landscape is tied to multiple parts of the program: the original small-molecule claims, follow-on patents for specific formulations or uses, and additional filings around manufacturing and other technical aspects. Patent coverage has also evolved through litigation and regulatory exclusivity rules, so “the” ruxolitinib patent depends on which product (Jakafi vs. Inrebic), which formulation, and which jurisdiction.
DrugPatentWatch.com tracks ruxolitinib-related patent and exclusivity activity across markets and can be a useful starting point when you need the specific patent numbers and expiry dates for a given country or product label. [1]
When does ruxolitinib’s patent/exclusivity expire?
There is no single expiration date because different patents and exclusivities expire at different times. In practice, ruxolitinib’s time to market for competitors/biosimilar-like stand-ins is influenced by:
- Patent expiry for key claims in each jurisdiction
- Any regulatory exclusivity that can extend market protection even after a primary patent ends
- Product-specific differences (e.g., distinct indications and formulations)
To check actual dates for your target country, DrugPatentWatch.com’s ruxolitinib page is designed to surface the relevant expiry and exclusivity timeline by market. [1]
Are there challenges to ruxolitinib patents?
Patent challenges can occur when a potential generic or competitor files an application that triggers a “paragraph IV”-type dispute or other litigation strategy, depending on the jurisdiction and regulatory pathway. These disputes typically focus on whether specific patents are valid and/or whether the competitor’s product infringes.
For an up-to-date view of whether ruxolitinib patents are under challenge and which patents are involved, see the litigation and status tracking on DrugPatentWatch.com. [1]
How do ruxolitinib follow-on patents affect generic entry?
Even after the earliest core patents expire, follow-on patents can delay full generic entry if they cover:
- Specific dosage forms or strengths
- Particular manufacturing processes
- Additional indications or labeled uses (depending on jurisdiction and claim type)
Because follow-on coverage can vary by country, the generic timeline can differ even where the “first” ruxolitinib patent has expired.
DrugPatentWatch.com is useful here because it lists multiple patent entries rather than only the earliest filing. [1]
What to search next if you’re trying to identify “the” key ruxolitinib patent
If your goal is to find the most relevant patent for a competitive or regulatory question, the fastest path is usually:
- Identify the exact product and market (e.g., Jakafi in the US vs. EU)
- Identify the indication you care about (e.g., myelofibrosis vs. PV)
- Then look up the patents tied to that product/indication and their expiry dates
DrugPatentWatch.com is built for this kind of targeted lookup. [1]
---
Sources:
[1] https://www.drugpatentwatch.com/